Background: Although the Skindex-29 is among the most commonly used health-related quality of life instruments in dermatology, the interpretation of obtained scores is not well documented. Objective: To create categories of the scores of the Skindex-29. Methods: The Skindex-29 scores of454 Italian patients with 6 distinct skin diseases from a specialized center were analyzed using mixture analyses. The validity of the obtained categorizations was tested. Results: Mixture analysis showed 4 distinct components (categories) for the emotion and functioning scale and 5 for the symptom scale. The total Skindex-29 score was categorized into 4 levels. As expected, patients with inflammatory diseases had higher levels of impairment, those with vitiligo and alopecia areata had low symptom levels and those with nevi were predominantly located in the lower categories for each of the scales. Conclusion: The proposed categories of the Skindex-29 may ease the interpretation of obtained continuous scores.

Keywords:
Categorization, distribution-based, Health-related quality of life, Psychometrics, Skindex-29
1.
Chren MM, Lasek RJ, Flocke SA, Zyzanski S: Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997;133:1433–1440.
2.
Both H, Essink-Bot ML, Busschbach JJ, Nijsten T: Critical review of generic and dermatology specific health related quality of life instruments. J Invest Dermatol 2007;127:2726–2739.
3.
Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY: Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol 2005;125:659–664.
4.
Nijsten TE, Sampogna F, Chren MM, Abeni DD: Testing and reducing Skindex-29 using Rasch analysis: Skindex-17. J Invest Dermatol 2006;126:1244–1250.
5.
Abeni D, Picardi A, Pasquini P, Melchi CF, Chren MM: Further evidence of the validity and reliability of the Skindex-29: an Italian study on 2,242 dermatological outpatients. Dermatology 2002;204:43–49.
6.
Haughton D: Packages for estimating finite mixtures: a review. Am Stat 1997;51:194–204.
7.
Böhning D, Dietz E, Schlattmann P: Recent developments in computer-assisted analysis of mixtures. Biometrics 1998;54:525–536.
8.
Nijsten T, Unaeze J, Stern RS: Refinement and reduction of the Impact of Psoriasis Questionnaire: classical test theory vs Rasch analysis. Br J Dermatol 2006;154:692–700.
9.
Sampogna F, Tabolli S, Mastroeni S, Di Pietro C, Fortes C, Abeni D: Quality of life impairment and psychological distress in elderly patients with psoriasis. Dermatology 2007;215:341–347.
10.
Sampogna F, Picardi A, Chren MM, et al: Association between poorer quality of life and psychiatric morbidity in patients with different dermatological conditions. Psychosom Med 2004;66:620–624.
11.
Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR: Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002;77:371–383.
12.
Testa MA: Interpretation of quality-of-life outcomes: issues that affect magnitude and meaning. Med Care 2000;38(9 suppl):II166–II174.
13.
Nijsten T, Meads DM, de Korte J, et al: Cross-cultural inequivalence of dermatology-specific health-related quality of life instruments in psoriasis patients. J Invest Dermatol 2007;127:2315–2322.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.